Padlock Therapeutics
Cambridge · Founded 2014
About Padlock Therapeutics
Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock was founded by scientists at The Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures. Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.
Company Facts
- Founded: 2014
- Legal name: Padlock Therapeutics, Inc.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 10,001+
- Estimated revenue: $1M – $10M
- Total funding: $37.7M
- Funding stage: M&A
- Last round: Series A (Dec 2014)
- Website: padlocktherapeutics.com
- Phone: (978) 381-9601
Social Profiles
Canonical: https://fsome.com/organization/padlock-therapeutics-8368612 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.